ClinicalTrials.Veeva
Menu

Find clinical trials for Triple Negative Breast Cancer in Chicago, IL

CTV is a public benefit provided by Veeva Systems to help you find the most relevant clinical trials for you and your loved ones

Related conditions:

Breast Cancer
Cancer
Carcinoma
Squamous Cell Carcinoma of Head and Neck
Non-Small-Cell Lung Carcinoma
Endometrial Cancer
Squamous Cell Carcinoma

Triple Negative Breast Cancer trials near Chicago, IL, USA:

Locations recently updated

Effects of MK-3475 (Pembrolizumab) on the Breast Tumor Microenvironment in Triple Negative Breast Cancer (Pembro/IORT)

Assess response to pembrolizumab in both primary tumor, normal breast stroma, circulating lymphocytes and serum exosomes in treatment naive ...

Enrolling
Triple Negative Breast Cancer
Drug: Merck 3475 Pembrolizumab
Radiation: Intraoperative radiation therapy (IORT)

Phase 1

Eileen Connolly

Maywood, Illinois, United States and 2 other locations

This research study involves testing the safety and efficacy of an investigational intervention for patients with triple-negative b ...

Enrolling
Breast Cancer
Triple Negative Breast Cancer
Drug: Pembrolizumab
Drug: Sacituzumab Govitecan

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Chicago, Illinois, United States and 9 other locations

or paclitaxel (cohort 1) or with sacituzumab govitecan-hziy (cohort 2) in patients with non-surgically removable locally advanced or metastatic triple...

Active, not recruiting
Triple-Negative Breast Cancer
Drug: Sacituzumab Govitecan-hziy
Drug: Magrolimab

Phase 2

Gilead Sciences
Gilead Sciences

Skokie, Illinois, United States and 44 other locations

The purpose of this study is to determine if a combination of two drugs ipatasertib and atezolizumab works as a treatment for residual cancer...

Active, not recruiting
Breast Cancer
Triple Negative Breast Cancer
Drug: Atezolizumab
Drug: Sacituzumab govitecan

Phase 2

Dana-Farber Cancer Institute
Dana-Farber Cancer Institute

Chicago, Illinois, United States and 8 other locations

and to evaluate the efficacy of this combination in advanced HER2 negative breast cancer that is triple negative...

Active, not recruiting
TNBC - Triple-Negative Breast Cancer
Drug: Talazoparib
Drug: Gedatolisib

Phase 1, Phase 2

Kari Wisinski

Chicago, Illinois, United States and 4 other locations

in patients with unresectable, locally advanced or metastatic triple-negative breast cancer (TNBC) who received a...

Active, not recruiting
Triple Negative Breast Cancer
Drug: Sacituzumab Govitecan-hziy
Drug: Trilaciclib

Phase 2

G1 Therapeutics

Joliet, Illinois, United States of America and 21 other locations

This is a 3-arm study stratified by plasma ctDNA. Patients with residual TNBC disease after pre-operative therapy will be assigned to 1 of 3 Arms bas...

Enrolling
Breast Cancer
Triple Negative Breast Cancer
Drug: Inavolisib
Drug: Talazoparib

Phase 2

Bryan Schneider, MD

Chicago, Illinois, United States and 12 other locations

This pilot study will provide preliminary data regarding the role of PIS in predicting the benefit of immune checkpoint inhibition with or without ch...

Active, not recruiting
Triple Negative Breast Cancer
Drug: Capecitabine
Drug: Nivolumab

Phase 2

Georgetown University
Georgetown University

Chicago, Illinois, United States and 3 other locations

This trial studies ladiratuzumab vedotin (LV) with pembrolizumab in patients with triple-negative breast cancer. -...

Active, not recruiting
Triple Negative Breast Neoplasms
Drug: Pembrolizumab
Drug: ladiratuzumab vedotin

Phase 1, Phase 2

Seagen
Seagen

Maywood, Illinois, United States and 49 other locations

selective inhibition of phosphoinositide-3-kinase (PI3K)-gamma, in combinations with Tecentriq and Abraxane (nab-paclitaxel) in front-line triple...

Active, not recruiting
Breast Cancer
Renal Cell Carcinoma
Drug: nab-paclitaxel
Drug: Bevacizumab

Phase 2

Infinity Pharmaceuticals
Infinity Pharmaceuticals

Chicago, Illinois, United States and 23 other locations

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems